Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion for ...
The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...
The US FDA has approved mosunetuzumab-axgb (Lunsumio VELO) as a subcutaneous formulation for the treatment of adult patients ...
The High Court of Karnataka has ruled in favour of Syngene and directed the Income Tax Authorities to refund the said amount ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback